Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 25;155(12):548-556.
doi: 10.1016/j.medcle.2020.07.014. Epub 2020 Dec 13.

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

Zulvikar Syambani Ulhaq  1 , Gita Vita Soraya  2
Affiliations

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

Zulvikar Syambani Ulhaq et al. Med Clin (Engl Ed). .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pooled reduction of C-Reactive Protein following administration of anti-IL-6R antibody in severe pneumonia. Figure shows mean ± standard error of the mean. n = 2–4 studies per group.
Fig. 2
Fig. 2
(A) Forest plot of studies reporting hazard ratio (HR) that investigates the mortality rate between Tocilizumab (TCZ) group and standard treatment (STD) group. (B–E) Forest plot of pooled studies evaluating mortality rate, invasive mechanical ventilation (IMV) requirement, ICU admissions, and the number of discharged patients between Tocilizumab (TCZ) group and standard treatment (STD) group, respectively.
Fig. 3
Fig. 3
Association between IL-6 −174G/C polymorphism with the severity of pneumonia. (A) C vs. G; (B) CC+GC vs. GG; (C) CC vs. GG.
See this image and copyright information in PMC

References

    1. Ulhaq Z.S., Soraya G.V. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020 doi: 10.1016/j.medmal.2020.04.002. pii:S0399-077X(20)30088-3. - DOI - PMC - PubMed
    1. Soraya G.V., Ulhaq Z.S. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis (March 30, 2020) Med Clin (Barc) 2020 doi: 10.1016/j.medcli.2020.05.017. - DOI - PMC - PubMed
    1. Tong Y., Wang Z., Geng Y., Liu J., Zhang R., Lin Q. The association of functional polymorphisms of IL-6 gene promoter with ischemic stroke: analysis in two Chinese populations. Biochem Biophys Res Commun. 2010;391:481–485. doi: 10.1016/j.bbrc.2009.11.084. - DOI - PubMed
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135W64. - DOI - PubMed
    1. Ulhaq Z.S., Garcia C.P. Inflammation-related gene polymorphisms associated with Parkinson's disease: an updated meta-analysis. Egypt J Med Hum Genet. 2020;21:14. doi: 10.1186/s43042-020-00056-6. - DOI

LinkOut - more resources